Overview

Preoperative Octreotide Treatment of Acromegaly

Status:
Completed

Trial end date:
2010-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate whether 6 months preoperative treatment with the somatostatin analogue octreotide improves the surgical outcome in patients with acromegaly.

Phase:

Phase 4

Details

Lead Sponsor:

St. Olavs Hospital

Collaborator:

Novartis

Treatments:

Octreotide